RARE is expected to report earnings to fall -15.13% to -175 cents per share on May 02

A.I.dvisor
at Tickeron.com
05/01/24
Loading...
RARE - Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Earnings Graph
Q1'24
Est.
$-1.75
Q4'23
Beat
by $0.18
Q3'23
Missed
by $0.16
Q2'23
Missed
by $0.16
Q1'23
Missed
by $0.34
The last earnings report on December 31 showed earnings per share of -152 cents, beating the estimate of -170 cents. P/B Ratio (12.837) is normal, around the industry mean (10.139). P/E Ratio (0.000) is within average values for comparable stocks, (115.202). RARE's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.468). RARE has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.015). P/S Ratio (7.205) is also within normal values, averaging (226.762). With 714.71K shares outstanding, the current market capitalization sits at 3.54B.
View a ticker or compare two or three
RAREDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of therapeutics for rare diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
60 Leveroni Court
Phone
+1 415 483-8800
Employees
1276
Web
https://www.ultragenyx.com